Candy Swift

There exist numerous sufferings resulted from miscellaneous diseases on the long march of human history. Threatened by these horrible illnesses, few people could fight back and survive until the...

It is estimated that as many as 65,000 patients worldwide are diagnosed with Hodgkin's lymphoma (HL) per year, and about 30% of patients fail after initial treatment (first-line combination...

What is CAR-T?CAR-T, Chimeric Antigen Receptor T-Cell Immunotherapy, is a new cell therapy that is improved in recent years. Like other immunotherapies, its basic principle is to clear cancer cells...

Scientists at the Garvan Medical Institute in Sydney have found that a class of "bad antibodies" in the immune system can provide crucial protection against invading microorganisms.It is called a "bad...

Antibody drugs have become the mainstay of modern biopharmaceutical development with high specificity, high stability and low toxicity. In recent years, antibody-drug conjugates (adc), the combination...

In February 2017, Ablynx filed an application for the listing of the nanobody Caplacizumab with the EMA of the European Medicines Agency, which is the first application for the market for nanobody...

Consisting of a fulfilling monoclonal antibody, an active cytotoxic drug and a suitable linker, antibody-drug conjugates (ADCs) are regarded as an efficient and innovative therapy for targeted...

Alzheimer's disease is one of the most common neurodegenerative disorder for the elderly. Early-onset Alzheimer's is rare that develops before age 65, primarily genetically influenced. Generally, the...

Comprised of a recombination monoclonal antibody and cytotoxic payloads through a linker, antibody drug conjugate (ADC) not only has a highly cytotoxic antitumor effect of small molecule drugs, but...

Bispecific antibody (BsAb) is an artificially engineered antibody that can simultaneously bind two specific epitopes or target proteins with some special biological functions, such as directly...

Cancer immunotherapy has made significant progress in several directions, most notably immune checkpoint inhibitors and CAR-T cell therapy. However, in recent years, bispecific antibody (bsAb) has...

The severe side effects of conventional chemotherapeutic treatments can’t be ignored since in most cases, the valid drug dose that can remove the tumor are too toxic for patients. To solve the...

Chimeric antigen receptor T cell (CAR-T) therapy is one of the most promising tumor targeted immunotherapy techniques, which has been proved effective in the treatment of a variety of...

Ordinary tumor therapeutic antibodies can only bind to a single antigen with a relatively low binding specificity is relatively low, which is prone to off-target effects. Bispecific antibodies (bsAbs...

CAR T immunotherapy(chimeric antigen receptor T cell immunotherapy) is one of the most potential technologies in the field of cancer therapy. Compared with other tumor treatment methods, such as...